The NOTCH3 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte cell line, designed to disrupt the NOTCH3 gene and abrogate Notch3 receptor function. This pooled knockout model provides a heterogeneous loss-of-function system suitable for studying the contribution of NOTCH3 to B-cell biology and lymphomagenesis without clonal selection, enabling researchers to assess population-level effects of Notch3 disruption. The Raji background offers a robust platform for investigating Notch signaling in an immunologically relevant context, given the cell line’s origin from Burkitt lymphoma and its established role in adaptive immune response research.
The host Raji cell line is a well-characterized Burkitt lymphoma-derived B lymphocyte model that retains key features of antibody-producing B cells and is extensively used to study B-cell malignancies, Epstein-Barr virus latency, and immune cell signaling. Raji cells endogenously express components of the Notch pathway and are responsive to Notch ligands, making them an appropriate host for examining Notch3-mediated gene regulation. Their derivation from a mature B-cell neoplasm provides a disease-relevant background for exploring the functional consequences of NOTCH3 inactivation in lymphoma biology, including impacts on proliferation, apoptosis, and differentiation.
NOTCH3 encodes a single-pass transmembrane receptor that mediates canonical Notch signaling upon engagement with DSL family ligands such as JAG1, JAG2, DLL1, and DLL4. Ligand binding triggers sequential proteolytic cleavages by ADAM10 and the gamma-secretase complex (containing PSEN1), releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus and forms a transcriptional activation complex with RBPJ and MAML1, driving expression of downstream effectors including HES1, HEY1, HEY2, MYC, CCND1, and BCL2. NOTCH3 activity is modulated by interacting factors such as NUMB and is integrated with other pathways, notably PI3K-Akt, MAPK, and NF-kappaB cascades, positioning it as a critical node in cell fate decisions, survival, and growth.
In the context of Raji cells, NOTCH3 knockout provides a powerful tool for dissecting Notch3-dependent mechanisms in B-cell lymphomagenesis. NOTCH3 overexpression has been implicated in various lymphoid malignancies and solid tumors, and its aberrant activation may contribute to oncogenic signaling through MYC upregulation and anti-apoptotic programs. By disrupting NOTCH3 in a Burkitt lymphoma cell line, researchers can evaluate how loss of Notch3 influences tumor cell behavior, including sensitivity to gamma-secretase inhibitors and other targeted therapies, as well as alterations in the transcriptome governed by RBPJ-MAML1 complexes. This model is also valuable for exploring crosstalk with the NF-kappaB pathway, which is frequently activated in lymphoma.
This NOTCH3 knockout product supports a range of advanced research applications, including functional characterization of Notch signaling in B-cell neoplasms, drug screening for gamma-secretase inhibitors or Notch-targeting agents, and mechanistic studies of ligand-dependent and -independent receptor activation. Typical assays include Western blotting for full-length NOTCH3 and cleaved NICD, RT-qPCR analysis of HES1 and HEY1 expression, flow cytometric assessment of surface NOTCH3, proliferation and apoptosis assays, co-immunoprecipitation of NICD-RBPJ interactions, and luciferase reporter assays for Notch transcriptional activity. For technical inquiries or to discuss custom applications, please contact Ascent Research.
